M. Davis & Sons Recognized as Top National Safety Leader by Associated Builders and Contractors
M. Davis announced it earned a National Safety Merit Award from Associated Builders and Contractors, presented at the 35th Excellence in Construction® Awards.
'We are honored to receive this recognition of our safety program. Training, culture, and most importantly, our employees are what makes our safety program world-class.' — Todd Moran, VP Risk Management
NEWARK, DE, UNITED STATES, March 17, 2025 / EINPresswire.com / -- M. Davis & Sons Recognized as Top National Safety Leader by Associated Builders and Contractors
M. Davis & Sons announced it has earned a National Safety Merit Award from Associated Builders and Contractors, which was presented at the 35th annual Excellence in Construction® Awards during ABC Convention 2025 in Las Vegas on Feb. 26.
M. Davis & Sons received the award for exemplary safety in the construction industry. The award was presented to only 52 contractors nationwide.
'We are honored to receive this recognition of our safety program. Training, culture, and most importantly, our employees are what makes our safety program world-class', states Todd Moran, Vice President of Risk Management.
The 2024 National Safety Excellence Award winners were selected from ABC member firms that achieved Diamond, Platinum or Gold status in ABC's STEP Safety Management System® in 2024, reflective of their 2023 safety performance data. During the selection process, contractors were judged on self-evaluation scores, lost workday case rates, total recordable incident rates, leading indicator use, process and program innovations and interviews conducted by members of ABC's National Health and Safety Committee.
'M. Davis & Sons exhibits an unrelenting commitment to jobsite safety, and that should be celebrated and honored,' said 2025 Chair of the ABC National Board of Directors David Pugh, partner, Bradley, Birmingham, Alabama. 'The leadership and employees at M. Davis make a choice every day to create a culture that refuses to compromise on safety, relentlessly ensuring every employee leaves the jobsite in the same or better condition every day. Among these safety winners are several ABC Top Performers, ranked by work hours. Thank you to these safety leaders for the example they set for this industry.'
The National Safety Excellence Awards are presented in three major North American Industry Classification System code categories: NAICS 236—Construction of Buildings; NAICS 237—Heavy and Civil Engineering Construction; and NAICS 238—Specialty Trade Contractors. See a complete list of winners on ABC's website.
For information about M. Davis & Sons, please contact: [email protected]
About M. Davis & Sons, Inc.
M. Davis & Sons, Inc. is a 155-year-old, fifth-generation, woman-owned industrial contractor that builds, installs and services facilities and manufacturing plants. With a focus on safety and quality workmanship, their construction, fabrication and maintenance capabilities produce customized, turnkey solutions for mechanical, electrical and control systems. M. Davis & Sons headquarters are in Newark, Delaware with other locations in Maryland and Pennsylvania. For more information, visit www.mdavisinc.com.
# # #
Elaine Buonopane
M. Davis & Sons, Inc.
+1 302-993-3365
Visit us on social media:
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
21 minutes ago
- Business Wire
MedX Announces the Engagement of Market Maker Consultant
MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) announces today the engagement of Red Cloud Securities Inc. (' Red Cloud ') to provide market making services to the Company. Pursuant to the agreement between Red Cloud and MedX, Red Cloud will be paid a monthly flat fee of $5,000, payable in advance in cash for the period of June 15, 2025 to September 15, 2025, and continuing thereafter on a monthly basis. Either party may terminate the agreement with not less than thirty-days' notice to the other party. As part of the services to be rendered to the Company, Red Cloud undertakes to use its best efforts to (i) maintain a reasonable and consistent bid and offer spread for the Company's common stock, (ii) maintain a reasonable board lot size for the bid and the offer of the Company's common stock on the TSX Venture Exchange, and (iii) supply liquidity using its own cash in hand. The services will mainly be rendered by Mr. Adam Smith who is acting at arm's length to the Company. As of the date of this announcement, Red Cloud, together with Mr. Adam Smith, own securities of the Company in the form of common shares. The engagement of Red Cloud remains subject to the acceptance of the TSX Venture Exchange. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit About Red Cloud Headquartered in Toronto, Ontario, Red Cloud is registered as an Investment Dealer in Ontario, Quebec, Alberta and British Columbia and is a member of the Investment Industry Organization of Canada (IIROC). It is focused on providing unique comprehensive capital market services and innovative financing alternatives to the junior resource sector. Red Cloud was founded by capital markets professionals who designed the firm to service public and private companies. This solution is a comprehensive platform that provides a full range of unconflicted corporate access services. Offering these services as a unified platform provides the ultimate value proposition for issuer clients. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Yahoo
22 minutes ago
- Yahoo
StopTheBleed.com Launches As A Dedicated Resource for Bleeding Control Kits
LELAND, N.C., June 12, 2025 /PRNewswire/ -- In recognition of the 10th anniversary of the STOP THE BLEED® initiative, Rescue Essentials is proud to announce the launch of a streamlined e-commerce destination for officially licensed STOP THE BLEED® kits and mass casualty response solutions. Designed to help organizations of all sizes prepare for bleeding emergencies, provides expertly curated kits for schools, public buildings, factories, offices, and anywhere else traumatic bleeding can happen. Each kit is built at our North Carolina facility with trusted components from Rescue Essentials and other leading manufacturers such as SAM Medical and North American Rescue " makes it easier than ever for people to find the exact bleeding control kits they need, whether to comply with local legislation or simply to be better prepared," said Jim Seidel, Rescue Essentials CEO. "Our team is here to assist with product selection, identify applicable state requirements, and even help customers locate available grant funding to support their preparedness goals." As a licensed partner of the U.S. Department of Defense's STOP THE BLEED® program, Rescue Essentials is committed to supporting this international public health initiative, which empowers bystanders to take action and save lives in the critical moments following a traumatic injury. represents Rescue Essentials' continued dedication to delivering high-quality, accessible medical response products and training support to first responders, safety officials and everyday heroes across the country. About Rescue Essentials Since 2007, Rescue Essentials has remained focused on its original goal — to offer top quality tactical, emergency, combat, and outdoor medical products at affordable prices, delivered in a timely manner. Rescue Essentials' core capabilities include the design, manufacture, and assembly of purpose-built trauma and medical kits for law enforcement, EMS and government agencies. Rescue Essentials, a division of Tri-Tech Forensics, Inc., is based in Leland, N.C. View original content to download multimedia: SOURCE Tri-Tech Forensics
Yahoo
23 minutes ago
- Yahoo
Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Second site, Regional Medical Oncology Center, also activated Recent Phase 1b clinical study results concluded continuous low dose lenalidomide provides meaningful efficacy and improved tolerability with no grade >3 drug-related hematologic toxicity PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. ('Starton'), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study's lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial's second active clinical site. 'We are excited to announce this major milestone in our mission to bring breakthrough therapies to patients. This marks the next phase of development for our lead candidate, STAR-LLD, and represents a significant step forward for the entire team," stated Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics. 'We expect this study to expand on what we observed in our prior Phase 1b study, that continuous low-dose lenalidomide provides meaningful efficacy and improved tolerability,' added Dr. Jamie Oliver, Starton's Chief Medical Officer. 'The expanded cohort and dose escalation will help us determine the most effective dose, with the goal of maintaining acceptable safety and tolerability.' Starton, which recently presented the results of the Phase 1b portion of the study at the 2025 American Association for Cancer Research, will assess the safety and tolerability of low-dose lenalidomide in heavily treated MM patients. Continuous SC infusion (STAR-LLD) in combination with dexamethasone and a protease inhibitor (PI) will be compared to oral lenalidomide (Revlimid®) in combination with dexamethasone and a PI. The study will include at least 24 patients randomized to STAR-LLD and oral lenalidomide (Revlimid®). Up to 45 additional patients may be enrolled to identify the optimal dose for a future registrational study (based on ORR vs dose vs Grade 3-4 toxicity). Starton anticipates opening approximately 10 clinical sites. About STAR-LLD STAR-LLD is a continuous delivery lenalidomide (LLD) in development to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD and 20% of animals in this cohort were tumor-free after 100 days, compared to a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1b clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (1 CR and 5 PRs); no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy. The study concluded that continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade > 2 drug-related hematologic toxicity. About Starton Therapeutics Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer live better, for longer. Starton's proprietary technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit Forward Looking Statements All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute 'forward-looking statements.' Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and except as required by law, Starton undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Investor Relations Contact Alex StarrManaging Director LifeSci Advisors astarr@ in to access your portfolio
